Despite the outcome, VE202 was well tolerated. Most adverse events were mild or moderate, with no reports of treatment-related serious adverse events. Further analyses on bacterial colonisation and ...

Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, said: “The SURPASS-CVOT results show that Mounjaro preserved the cardioprotective benefit of Trulicity, a GLP-1 ...